Abstract: A pyrroloquinoline compound of the following formula is disclosed: ##STR1## wherein H,C.sub.1-6 alkyl,R.sup.1 is: ##STR2## wherein R is H, C.sub.1-10 alkyl, or C.sub.1-6 alkyloxycarbonyl; R.sup.2 is:H,C.sub.1-6 alkyl, ##STR3## wherein R.sup.5 is C.sub.1-10 alkyl, aryl, or aryl C.sub.1-10 alkyl; R.sup.3 is:(CH.sub.2).sub.n NHR wherein R is H, C.sub.1-6 alkyl, or C.sub.1-6 alkyloxycarbonyl; ##STR4## R.sup.4 is: H,C.sub.1-6 alkyl,C.sub.1-6 alkyloxycarbonyl,RCH.sub.2 --, wherein R is H, C.sub.1-6 alkyl or aryl, or ##STR5## X is O, or NR.sup.6 wherein R.sup.6 is equal to H or C.sub.1-6 alkyl and n is an integer from 1-3.The compounds of the invention exhibit bradykinin antagonist activity as well as activity with .alpha.-adrenergic, histaminergic, and muscarinic receptors.

Abstract: 4-(2-Methyl-2-hydroxypropylamino)-5,6-dihydrothieno[2,3-b]thiopyran-2-sulfo namide-7,7-dioxide is a major mammalian metabolite of 4-(2-methylpropylamino)-5,6-dihydrothieno[2,3-b]thiopyran-2-sulfonamide-7, 7-dioxide and is itself an active carbonic anhydrase inhibitor useful in the treatment of ocular hypertension by topical administration.

Abstract: Fluoro-and hydroxy-derivatives of 5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imines wherein the substituents are on non-benzenoid carbons are active anticonvulsants and antagonists of N-methyl-D-aspartate.

Abstract: 1-Aryloxy-3-(substituted aminoalkylamino)-2-propanols and pharmaceutically acceptable salts thereof have .beta.-adrenergic blocking activity with some cardioselectivity and hence are useful as anti-hypertensive, antianginal, antiarrhythmic and cardioprotective agents and in the treatment of elevated intraocular pressure such as glaucoma.

Abstract: 1-Aryloxy-3-(substituted aminoalkylamino)-2-propanols and pharmaceutically acceptable salts thereof have .beta.-adrenergic blocking activity with some cardioselectivity and hence are useful as antihypertensive, antianginal, antiarrhythmic and cardioprotective agents and in the treatment of elevated intraocular pressure such as glaucoma.

Abstract: There are disclosed cyclic octapeptide analogs of the tridecapeptide, neurotensin.

Abstract: There are disclosed metabolically protected linear analogs of the carboxy terminal pentapeptide fragment of the tridecapeptide, neurotensin.

Abstract: Synthetic novel cyclic hexapeptides having the structure:Cyclo[(N-alkylamino acid)-X-(N-alkylamino acid)'-X-(N-alkylamino acid)"-X]wherein (N-alkylamino acid), (N-alkylamino acid)' and (N-alkylamino acid)" have the structure: ##STR1## wherein R.sup.1 is a lower alkyl group having 1 to 3 carbon atoms and R.sup.2 is hydrogen and methyl or R.sup.1 and R.sup.2 are --CH.sub.2 --N, n being an integer 2 or 3, and form a 4- or 5- membered ring; and X is D- or L-Ala, D- or L-Phe, D- or L-Leu, D- or L-p-halophenylalanyl or D- or L-p-nitrophenylalanyl, with the proviso that when R.sup.1 is methyl and R.sup.2 is hydrogen, X is not D-Ala are prepared. Oral administration of these cyclic peptides improves the digestive efficiency of certain herbivorous animals.

Abstract: Novel tripeptides are disclosed. These tripeptides have anti-depressant activity and thyrotropin releasing hormone activity. Processes for preparing these tripeptides are also disclosed.